Dow Jones
32.105,25 +75,14 (+0,23%) Nasdaq
11.787,40 +117,44 (+1,01%) Nikkei 225
27.352,77 -66,84 (-0,24%) EUR/USD
1,0830 -0,0007 (-0,06%) Bitcoin EUR
26.100,12 +790,29 (+3,12%) CMC Crypto 200
618,15 +20,69 (+3,46%)
Mauna Kea Technologies SA (0P5I.L)
| Chiusura precedente | 0,6400 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 189.901 |
| Beta (5 anni mensile) | 1,59 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3530 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Level
Dose increase of R327 Dose increase of R327 Highlights: 36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good safety and tolerability at 1,000mg Independent Safety Committee affirms ‘low-dose’ cohort clinical trial complete, endpoints achieved – recommends ‘high dose’ cohort dosing to beginCommittee clears cohort five (R327 – 2,000mg IV) dosing – subjects recruited and dosing underway SYDNEY, Australia, April 13, 2022 (GLOBE NEWSWIRE)
- GlobeNewswire
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Intellectual Property Department of the Hong Kong Special Administrative Region has granted patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection,” furthering marketing and manufacturing exclusivity to February 2037. “As we continue to build our patent portfolio in key geogr
